NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
NovaBridge Biosciences (Nasdaq: NBP) announced that senior management will present at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026 at 3:10 PM ET.
The company presentation and one-on-one investor meetings will be webcast and available on NovaBridge’s investor relations website for 90 days.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Investor conference | Neutral | -1.9% | Announced participation in H.C. Wainwright BioConnect investor conference. |
| Apr 22 | Leadership change | Positive | -0.4% | Appointed President and CCO to strengthen commercial strategy for pipeline. |
| Apr 07 | Earnings and update | Neutral | -1.2% | Reported 2025 results and highlighted givastomig and VIS-101 pipeline progress. |
| Mar 16 | Regulatory update | Positive | +1.4% | Announced FDA alignment on potential accelerated approval path for givastomig. |
| Mar 09 | Clinical results | Positive | +0.1% | Reported positive Phase 2a wet AMD data for VIS-101 with durability signals. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news, including conferences and positive clinical/regulatory updates, has mostly led to modest price moves, with one divergence on a senior hire announcement.
Over the last few months, NovaBridge has mixed routine visibility events with substantive pipeline and regulatory progress. On Mar 9, 2026, positive Phase 2a data for VIS-101 was announced, followed by an FDA Type B meeting update for givastomig on Mar 16, 2026. Full-year 2025 results and a business update arrived on Apr 7, 2026, and a senior commercial leader was appointed on Apr 22, 2026. Another investor conference appearance was disclosed on May 12, 2026. Today’s Jefferies conference notice continues that investor-outreach pattern.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., May 28, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines that address significant unmet needs, today announced that members of the Company’s senior management team will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026.
Conference details are as follows:
2026 Jefferies Global Healthcare Conference
Format: Company Presentation and one-on-one investor meetings
Date: Thursday, June 4, 2026
Presentation time: 3:10 PM ET
Webcast Link: Here
The webcast of the Jefferies presentation will be accessible on the News & Events section of the Investor Relations page on the NovaBridge website for 90 days.
About NovaBridge
NovaBridge is a global biotechnology platform company committed to accelerating access to innovative medicines. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. By bridging science, strategy, and execution, NovaBridge enables transformative therapies to progress rapidly from discovery toward patients in need.
The Company’s differentiated pipeline is led by givastomig, a potential first-in-class and best-in-class, Claudin 18.2 X 4-1BB bispecific antibody, and VIS-101, a purpose-designed, potential best-in-class, dual VEGF-A X ANG-2 inhibitor.
Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. The product candidate is being evaluated in a global, randomized Phase 2 study, following the recent announcement of positive topline results from a Phase 1b, multi-center, open label study in first line gastric cancer. The Company is also collaborating with its partner, ABL Bio, for the development of ragistomig, a bispecific antibody integrating PD-L1 as a tumor engager and 4-1BB as a conditional T cell activator, in solid tumors. Additionally, NovaBridge owns worldwide rights outside of China to uliledlimab, an anti-CD73 antibody that targets adenosine-driven immunosuppression in cancer.
VIS-101 targets VEGF-A and ANG-2 to provide more rapid, robust and durable treatment responses for patients with retinal vascular diseases including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. VIS-101 has completed a randomized, dose-ranging Phase 2a study for wet AMD and expects to initiate a dose-determining Phase 2b study in H2 2026. NovaBridge is the majority shareholder of Visara, Inc., and Visara controls global rights to VIS-101, outside of Greater China and certain countries in Asia.
For more information, please visit www.novabridge.com and follow us on LinkedIn.
NovaBridge Investor & Media Contacts
NovaBridge Biosciences
+1-240-745-6330
IR@novabridge.com
Bill Begien, VP of Investor Relations
bill.begien@novabridge.com
PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
